Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
2017 · Nature Genetics · 566 citations
https://doi.org/10.1038/ng.3990
D
David R. Gandara
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.1K
Papers
54.6K
Citations
100
h-index
465
i10-index
David R. Gandara is an academic researcher from Comprehensive Blood & Cancer Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Genomics and Diagnostics. The author has an h-index of 100, co-authored 948 publications.
ORCID: 0000-0003-1784-048XPapers by this author
worksGeospatial Resolution of Human and Bacterial Diversity with City-Scale Metagenomics
2015 · Cell Systems · 344 citations
https://doi.org/10.1016/j.cels.2015.01.001
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials
2020 · Journal of Thoracic Oncology · 192 citations
https://doi.org/10.1016/j.jtho.2020.09.022
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
2017 · The Lancet Oncology · 170 citations
https://doi.org/10.1016/s1470-2045(17)30691-5
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
2024 · Nature · 123 citations
https://doi.org/10.1038/s41586-024-07943-7
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
2019 · Journal of Thoracic Oncology · 86 citations
https://doi.org/10.1016/j.jtho.2019.05.029
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat